GEN Exclusives

More »

GEN News Highlights

More »
Mar 1, 2007

Athersys Completes Manufacturing of Multistem for Clinical Trials

  • Lonza has successfully produced a clinical-grade master cell bank and initial product doses intended to support Athersys’ MultiStem program in clinical trial activity in 2007 and 2008.

    Athersys is developing MultiStem to treat patients for certain cardiovascular disorders, stroke, bone marrow transplantation, and oncology support. It is a multipotent adult progenitor cell (MAPC)-based product. The stem cells are isolated from the bone marrow and other nonembryonic tissue sources that have the potential to develop into a range of cell types and can be expanded ex vivo while retaining their potency, according to an Athersys. 

    “We believe that our master cell bank gives us the potential to manufacture hundreds of thousands or more MultiStem doses from a single donor, enabling us to advance multiple programs into clinical development, and treat patients with a variety of conditions,” comments B.J. Lehmann, president and COO at Athersys.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »